KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $302 from $299 and keeps an Overweight rating on the shares post Q2 on higher estimates. The firm views ResMed’s Q2 release as largely positive and supportive of its overall thesis, given a solid revenue beat and continued upside to gross margins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: